BackTable Tumor Board
BackTable Tumor Board
Podcast Description
BackTable Tumor Board is a multi-disciplinary podcast for healthcare professionals that play an active role in cancer care. Season One features in-depth conversations on the topic of Hepatocellular Carcinoma (HCC) provided by a group of medical oncologists, interventional radiologists, hepatobiliary surgeons, hepatologists, and patient coordinators. Stay tuned for the next season!
Podcast Insights
Content Themes
The podcast explores various aspects of hepatocellular carcinoma, including treatment options, complex case discussions from tumor board meetings, and insights on the role of surgery, interventional oncology, and transplantation. Episodes feature detailed case reviews, such as the principles of practice in HCC tumor boards and tips for starting a career in interventional oncology.
BackTable Tumor Board is a multi-disciplinary podcast for healthcare professionals that play an active role in cancer care.
Get caught up on the cutting edge colorectal cancer trial data from ESMO 2025 with this 30-minute BackTable Tumor Board recap! Featuring medical oncologists Dr. Jonothan Mizrahi and Dr. Jun Gong.
—
SYNPOSIS
The doctors discuss the DESTINY-CRC02 trial with focus on HER-2 positive metastatic colorectal cancer, the DYNAMIC-III and Pegasus studies regarding CTDNA-guided therapies, and the pivotal STELLAR-303 study for treatment-refractory microsatellite stable colorectal cancer. They also review the implications of NICHE-2 and FOxTROT studies on neoadjuvant chemotherapy versus immunotherapy for MSI high patients. Emphasis is placed on the real-world practice applications of these study findings, potential treatment shifts, and how these new trial results will impact future guidelines in colorectal cancer care.
—
TIMESTAMPS
00:00 – Introduction
01:25 – Overview of ESMO 2025 Annual Congress
13:50 – cTDNA Monitoring in Clinical Practice
16:24 – STELLAR-303 Study: Immunotherapy in MSS Colorectal Cancer
20:40 – Neoadjuvant Immunotherapy for MSI High Colorectal Cancer
26:39 – DESTINY-CRC02 Study: Final Analysis
29:30 – Conclusion and Outro
—
RESOURCES
DESTINY-CRC02 Trial
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00380-2/abstract
DYNAMIC-III Trial
https://www.nature.com/articles/s41591-025-04030-w
STELLAR-303 Trial
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02025-2/abstract
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.